Canopy Growth Corporation

NasdaqGS:CGC Voorraadrapport

Marktkapitalisatie: US$376.9m

Canopy Growth Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Canopy Growth de winst en omzet met respectievelijk 36.5% en 11.2% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 71.9% per jaar.

Belangrijke informatie

36.5%

Groei van de winst

71.89%

Groei van de winst per aandeel

Pharmaceuticals winstgroei14.4%
Inkomstengroei11.2%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt27 Apr 2026

Recente toekomstige groei-updates

Geen updates

Recent updates

Seeking Alpha • Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

Canopy Growth: Zombie Financials As Delisting Threat Looms

Summary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
Seeking Alpha • Mar 30

Cannabis Investors Should Sell Canopy Growth

Summary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak

Summary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results

Summary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Crashing Canopy Growth Is Still Not A Buy

Summary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty

Summary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Avoid Canopy Growth

Summary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Seeking Alpha • Oct 05

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Summary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Summary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Canopy Growth: Another Ugly Cannabis Report

Summary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
Seeking Alpha • Apr 26

Canopy Growth Set For U.S. Cannabis Markets

Summary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Canopy Growth Is Climbing, But It Won't Last

Summary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Summary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Summary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Avoid Canopy Growth After Failed Equity Sale

Summary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NasdaqGS:CGC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CAD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/2029420N/AN/AN/A1
3/31/2028387-131-66-614
3/31/2027368-126-62-565
3/31/2026288-143-88-705
12/31/2025278-327-87-79N/A
9/30/2025279-387-96-88N/A
6/30/2025275-516-133-124N/A
3/31/2025269-604-177-166N/A
12/31/2024277-477-163-155N/A
9/30/2024280-586-167-160N/A
6/30/2024287-602-191-185N/A
3/31/2024297-484-286-282N/A
12/31/2023293-999-407-400N/A
9/30/2023299-991-520-511N/A
6/30/2023317-1,025-576-566N/A
3/31/2023333-3,079-568-558N/A
12/31/2022367-3,051-559-544N/A
9/30/2022423-2,938-583-568N/A
6/30/2022466-2,766-550-521N/A
3/31/2022476-255-594-546N/A
12/31/2021557-428-587-517N/A
9/30/2021569-1,223-552-437N/A
6/30/2021572-1,244-644-513N/A
3/31/2021547-1,745-622-466N/A
12/31/2020506-2,348-803-579N/A
9/30/2020477-1,535-1,033-681N/A
6/30/2020419-1,244-1,282-733N/A
3/31/2020399-1,321-1,495-773N/A
12/31/2019385-415-1,610-802N/A
9/30/2019344-256N/A-709N/A
6/30/2019291-832N/A-626N/A
3/31/2019226-736N/A-535N/A
12/31/2018155-398N/A-332N/A
9/30/201894-464N/A-257N/A
6/30/201888-148N/A-137N/A
3/31/201878-67N/A-82N/A
12/31/201770-21N/A-60N/A
9/30/201758-19N/A-41N/A
6/30/201749-13N/A-36N/A
3/31/201740-8N/A-27N/A
12/31/201630-1N/A-14N/A
9/30/201624-7N/A-15N/A
6/30/201618-8N/A-14N/A
3/31/201613-3N/A-14N/A
12/31/201580N/A-14N/A
9/30/201561N/A-12N/A
6/30/20153-5N/A-10N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CGC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CGC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CGC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CGC ( 11.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.6% per jaar).

Hoge groei-inkomsten: De omzet van CGC ( 11.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CGC naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/20 06:20
Aandelenkoers aan het einde van de dag2026/05/20 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Canopy Growth Corporation wordt gevolgd door 23 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)